
GSK-3β inhibitor 1
CAS No. 187325-53-7
GSK-3β inhibitor 1( —— )
Catalog No. M22450 CAS No. 187325-53-7
GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.GSK-3β inhibitor 1(compound 3a) inhibits GSK-3β with IC50 4.19 nM.?In a cell-based assay 3a shows no significant leucocyte toxicity at 10 M and is moderately cytotoxic against A549 cells.?
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 149 | Get Quote |
![]() ![]() |
10MG | 262 | Get Quote |
![]() ![]() |
25MG | 439 | Get Quote |
![]() ![]() |
50MG | 644 | Get Quote |
![]() ![]() |
100MG | 888 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameGSK-3β inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.GSK-3β inhibitor 1(compound 3a) inhibits GSK-3β with IC50 4.19 nM.?In a cell-based assay 3a shows no significant leucocyte toxicity at 10 M and is moderately cytotoxic against A549 cells.?
-
DescriptionGSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.GSK-3β inhibitor 1(compound 3a) inhibits GSK-3β with IC50 4.19 nM.?In a cell-based assay 3a shows no significant leucocyte toxicity at 10 M and is moderately cytotoxic against A549 cells.?Compound 3a demonstrated high antidiabetic efficacy in obese streptozotocin-treated rats improving glucose tolerance at a dose of 50 mg/kg body weight thus representing an interesting lead for further optimization.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3β
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number187325-53-7
-
Formula Weight222.24
-
Molecular FormulaC14H10N2O
-
Purity>98% (HPLC)
-
SolubilityDMSO : 30 mg/mL?(134.99 mM;?Need ultrasonic)
-
SMILESO=C1Nc2ccccc2\C1=C\c1ccccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lozinskaya NA, et al. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. Bioorg Med Chem. 2019 May 1;27(9):1804-1817.
molnova catalog



related products
-
GSK-3β inhibitor 14
GSK-3β inhibitor 14 (1,5-Benzothiazepin-4(5H)-one, 2,3-dihydro-2-methyl-5-(phenylmethyl)-) is a weak GSK-3β inhibitor, IC50﹥ 100μM.
-
GSK-3 inhibitor 4
GSK-3 inhibitor 4 is an orally active and brain-permeable compound that acts as a triple inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM (CDK2), and 0.68 μM (CDK5).
-
CDK8-IN-12
CDK8-IN-12 is a selective, potent and orally active inhibitor of CDK8 (Ki: 14 nM) and is an anti-cancer agent.